Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Time to Sell?

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF) gapped down before the market opened on Wednesday. The stock had previously closed at $16.00, but opened at $14.90. Ono Pharmaceutical shares last traded at $14.90, with a volume of 1,000 shares traded.

Wall Street Analysts Forecast Growth

Separately, Zacks Research cut shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 4th. One analyst has rated the stock with a Hold rating. According to data from MarketBeat.com, Ono Pharmaceutical presently has an average rating of “Hold”.

Ono Pharmaceutical Trading Down 6.9%

The company has a debt-to-equity ratio of 0.08, a current ratio of 3.28 and a quick ratio of 2.86. The company’s 50 day simple moving average is $15.06 and its two-hundred day simple moving average is $14.87. The company has a market cap of $7.00 billion, a PE ratio of 14.19 and a beta of 0.38.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.